

SCIENTIFIC REPORTS



OPEN

An Artificial Reaction Promoter Modulates Mitochondrial Functions via Chemically Promoting Protein Acetylation

Received: 19 April 2016

Accepted: 14 June 2016

Published: 04 July 2016

Yutaka Shindo¹, Hirokazu Komatsu², Kohji Hotta¹, Katsuhiko Ariga² & Kotaro Oka¹

Acetylation, which modulates protein function, is an important process in intracellular signalling. In mitochondria, protein acetylation regulates a number of enzymatic activities and, therefore, modulates mitochondrial functions. Our previous report showed that tributylphosphine (PBU₃), an artificial reaction promoter that promotes acetyltransfer reactions *in vitro*, also promotes the reaction between acetyl-CoA and an exogenously introduced fluorescent probe in mitochondria. In this study, we demonstrate that PBU₃ induces the acetylation of mitochondrial proteins and a decrease in acetyl-CoA concentration in PBU₃-treated HeLa cells. This indicates that PBU₃ can promote the acetyltransfer reaction between acetyl-CoA and mitochondrial proteins in living cells. PBU₃-induced acetylation gradually reduced mitochondrial ATP concentrations in HeLa cells without changing the cytoplasmic ATP concentration, suggesting that PBU₃ mainly affects mitochondrial functions. In addition, pyruvate, which is converted into acetyl-CoA in mitochondria and transiently increases ATP concentrations in the absence of PBU₃, elicited a further decrease in mitochondrial ATP concentrations in the presence of PBU₃. Moreover, the application and removal of PBU₃ reversibly alternated mitochondrial fragmentation and elongation. These results indicate that PBU₃ enhances acetyltransfer reactions in mitochondria and modulates mitochondrial functions in living cells.

Mitochondria are essential organelles for cellular energy metabolism and intracellular signalling for cell death, and protein acetylation plays important roles in the modulation of mitochondrial functions^{1–3}. Acetylation levels of mitochondrial proteins are regulated by the NAD⁺-dependent deacetylase activity of sirtuins. The mammalian genome encodes seven sirtuin isoforms, three of which are localized to mitochondria (SIRT3, 4, and 5)⁴. Among these, SIRT3 plays a major role in protein deacetylation and the resulting modification of enzymatic activities⁵. The knockout or inhibition of SIRT3 elicits hyperacetylation of mitochondrial proteins, resulting in a decrease in cellular ATP concentration *via* depolarization of the mitochondrial membrane potential^{6,7}, an increase in the production of reactive oxygen species^{8,9}, and alteration of mitochondrial morphology^{10,11}. SIRT3 is thus the main regulator of mitochondrial protein acetylation levels. However, the acetylation processes of mitochondrial proteins remain unclear. While the mitochondrial protein GCN5L1 has been shown to be related to one of the mitochondrial protein acetylation mechanisms¹², it is also possible that mitochondrial protein acetylation is caused by a reaction between lysine residues and acetyl-CoA in a non-enzymatic process^{13,14}. Hence, mitochondrial protein acetylation is regulated by both enzymatic and non-enzymatic processes, and controls mitochondrial functions.

“Artificial reaction promoters” are compounds that promote chemical reactions *in vitro* and also in cells. In our previous study, we demonstrated that the application of one such artificial reaction promoter, tributylphosphine (PBU₃), elicited the acetylation of a fluorescent probe in the mitochondria of HeLa cells¹⁵. PBU₃ probably enhanced the reactivity of acetyl-CoA in an acetyltransfer reaction in the cells, as well as *in vitro*, and facilitated a chemical reaction between acetyl-CoA and the fluorescent probe in the mitochondria. Based on this result, we hypothesized that PBU₃ non-enzymatically promotes the acetyltransfer reaction between acetyl-CoA and lysine residues of neighbouring proteins. If PBU₃ enhances the intracellular non-enzymatic acetyltransfer reaction between those

¹Department of Biosciences and Informatics, Faculty of Science and Technology, Keio University, 3-14-1 Hiyoshi, Kohoku-ku, Yokohama, Kanagawa 223-8522, Japan. ²MANA, National Institute for Materials Science, 1-1 Namiki, Tsukuba, Ibaraki 305-0044, Japan. Correspondence and requests for materials should be addressed to K.O. (email: oka@bio.keio.ac.jp)




Figure 1. PBU₃-induced acetylation of mitochondrial proteins. (A) Protein acetylation levels were compared using Western blotting probed with anti-acetylated lysine antibody in control and PBU₃-treated cells (5 mM and 10 mM for 10 min). Mitochondrial, cytoplasmic and nuclear proteins were run under the same experimental conditions in separate runs. Cox4, β -actin and PARP1 were blotted as a loading control for mitochondrial, cytoplasmic and nuclear proteins, respectively. Data are representative of $n = 3$ experiments. (B) Relative acetylation levels in the arrowed bands of mitochondrial protein were calculated from integrated densitometry values relative to Cox4 levels. Data were normalized using control values. PBU₃ elicited significant protein acetylation in the mitochondria. Bars represent the mean \pm SEM of three sets of data run in the same gel. *Indicates $P < 0.05$ (Dunnnett's test).

biological molecules, mitochondrial functions might be controlled by the application of an exogenous artificial reaction promoter, since the activities of a number of mitochondrial proteins are regulated by acetylation^{16–18}. In this study, we examined the ability of PBU₃ to promote the acetyltransfer reaction from acetyl-CoA to mitochondrial proteins and to modulate mitochondrial functions in living cells.

Results

PBU₃ promoted protein acetylation in the mitochondria. To verify our hypothesis that PBU₃ promotes the acetyltransfer reaction between acetyl-CoA and mitochondrial proteins, protein acetylation levels in mitochondria, cytoplasm, and nucleus were estimated by Western blotting using an anti-acetylated lysine antibody. The concentrations of PBU₃ used were the same as those used in our previous study measuring acetylation reactions using a fluorescent probe¹⁵. Exposure of HeLa cells to 5 mM and 10 mM PBU₃ for 10 min elicited acetylation of mitochondrial proteins, especially in the 30–55 kDa range (Fig. 1A). The acetylation signal increased significantly, depending on the PBU₃ concentration, in the indicated bands of mitochondrial proteins (Fig. 1B). No significant changes in protein acetylation level were observed in the cytoplasm or nucleus (Fig. 1A). Moreover, we observed that mitochondrial superoxide dismutase (SOD2), which is regulated by acetylation¹⁹, was also acetylated by the 10 min PBU₃ treatment (see Supplementary Fig. S1), indicating that PBU₃ induces acetylation of mitochondrial proteins.

To confirm that PBU₃ promotes acetyltransfer reaction between acetyl-CoA and mitochondrial proteins, we estimated cellular acetyl-CoA concentrations (Fig. 2). The concentration decreased in PBU₃-treated cells, suggesting that acetyl-CoA is the substrate for protein acetylation. However, a high concentration of PBU₃ might inhibit protein deacetylase, instead of promoting the acetyltransfer reaction, because PBU₃ also acts as an ion chelator and Zn²⁺ binds to SIRT3²⁰. We therefore confirmed that application of PBU₃ (1–20 mM) has no effect on the activity of SIRT3 *in vitro* (see Supplementary Fig. S2), indicating that PBU₃ does not inhibit protein deacetylation but promotes protein acetylation. Based on these results, we concluded that PBU₃ successfully promotes the acetyltransfer reaction from acetyl-CoA to the neighbouring proteins in mitochondria, which probably occurs because of the high concentration of mitochondrial acetyl-CoA.

The toxicity of PBU₃ was evaluated by exposing HeLa cells to PBU₃ for 10 min. Concentrations of less than 10 mM had no toxic effect on cell viability after 24 h (Fig. 3). Although exposure to PBU₃ at concentrations higher than 2 mM for 24 h or 5 mM for longer than 2 h decreased cell viability (see Supplementary Fig. S3), brief treatment to promote protein acetylation in mitochondria (less than 10 mM for 10 min) did not exhibit any toxic




Figure 2. Acetyl-CoA concentration decreased in PBU₃-treated cells. Cellular acetyl-CoA concentrations were measured and compared between the control and PBU₃-treated (5 mM for 10 min) cells. Data presented are mean \pm SEM of $n = 5$ samples each. *Indicates $P < 0.05$ (t -test).




Figure 3. Toxicity of 10 min exposure to PBU₃. Comparisons of HeLa cell viabilities 24 h after exposure for 10 min to representative concentrations of PBU₃, as assessed by MTT assay. Data presented are mean \pm SEM of $n = 5$ samples each from three different experiments. *Indicates $P < 0.05$ (Dunnett's test).

effects. These results indicate that short-term exposure to PBU₃ at an appropriate concentration promotes the acetyltransfer reaction non-invasively in living cells.

Candidate proteins acetylated by PBU₃. As shown in Fig. 2A, mitochondrial proteins in the 30–55 kDa range were strongly acetylated by PBU₃. We therefore aimed to identify the proteins contained in these bands using LC-MS/MS, and succeeded in identifying the following proteins: Succinyl-CoA synthetase subunit β (SUCB1); E3 ubiquitin-protein ligase (MARCH5); monoamine oxidase type A (AOFA); and serine β -lactamase-like protein (LACTB). Among these candidate proteins, SUCB1 is a tricarboxylic acid (TCA) cycle enzyme that catalyses the reaction of succinyl-CoA to succinate, and is involved in ATP production in mitochondria²¹. MARCH5 is involved in mitochondrial quality control and Drp1-dependent mitochondrial fission²². These results suggest that PBU₃-induced acetylation of mitochondrial proteins modifies mitochondrial functions. A number of other proteins are likely to be acetylated by PBU₃ in addition to the four candidates that we identified

PBU₃-induced protein acetylation affected ATP synthesis in mitochondria. It has been reported that the cellular ATP concentration is lower in SIRT3 knockout cells than that in normal cells¹⁰, indicating that protein acetylation inhibits ATP synthesis in mitochondria. We therefore examined the effect of PBU₃-induced protein acetylation on ATP concentration using the ATP sensor protein, ATeam²³. While 5 mM PBU₃ had no effect on the ATP concentration in cytoplasm (Fig. 4A), it elicited a gradual but significant decrease in the ATP concentration in mitochondria (Fig. 4B,C). The mitochondrial ATP concentration was lower than that in cytoplasm as reported before²³ (Fig. 4C). PBU₃ decreased the mitochondrial ATP concentration in a dose-dependent manner (0–10 mM; Fig. 4D).

To ascertain whether the PBU₃-induced decrease in ATP concentration was caused by protein acetylation in the mitochondria, we compared changes in ATP concentration resulting from PBU₃ application between normal cells and SIRT3-overexpressing cells (Fig. 4E). The decrease in ATP concentration was partially suppressed in the SIRT3-overexpressing cells, since it was attenuated by the protein deacetylase SIRT3 (Fig. 4F), indicating that PBU₃ modulates ATP concentration *via* mitochondrial protein acetylation.

The protein acetylation induced by PBU₃ thus resulted in a decrease in mitochondrial ATP concentration, probably due to the inhibition of enzymes involved in ATP production by acetylation: ATP synthase; the enzymes in the TCA cycle; and the electron transport chain^{24–27}. Pharmacological inhibition of mitochondrial ATP synthesis by oligomycin induced a similar magnitude of decrease in ATP concentration, and the collapse of the




Figure 4. PBu_3 -induced changes in ATP concentrations. **(A)** Time-course of cytoplasmic ATP concentration (mean \pm SEM of $n = 28$ cells from three different experiments) measured using the protein-based ATP sensor ATeam, localized to the cytoplasm (upper). PBu_3 (5 mM) was applied at 0 min. Representative fluorescence image and pseudo-colored images of an ATeam ratio are shown (lower). Pseudo-colored images show an ATeam ratio (YFP/CFP) ranging from 1.0 (blue) to 1.5 (red) at the indicated time after the application of PBu_3 . **(B)** Time-course of ATP concentration in mitochondria (mean \pm SEM of $n = 49$ cells from five different experiments), measured using ATeam localized to mitochondria. PBu_3 (5 mM) was applied at 0 min. Representative fluorescence image and pseudo-colored images of an ATeam ratio are shown (lower). **(C)** Comparison of the ATeam ratio (mean \pm SEM) before (averaged from -1 to 0 min) and after (averaged from 9 to 10 min) the application of PBu_3 , as shown in A and B. *Indicates $P < 0.05$ in t -test. **(D)** Change in the mitochondria-localized ATeam ratio (mean \pm SEM) after 10 min in response to the indicated concentrations of PBu_3 (0 mM: $n = 78$ cells from nine different experiments; 2.5 mM: $n = 21$ cells from four different experiments; 5 mM: $n = 42$ cells from four different experiments; 10 mM: $n = 37$ cells from four different experiments; and 20 mM: $n = 23$ cells from two different experiments). **(E)** ATeam (left) and SIRT3-mCherry (right) fluorescence images of the same region. ATeam signal was compared between SIRT3-mCherry overexpressing cells (arrows) and non-overexpressing cells (arrowheads). **(F)** Comparison of ATeam ratio (mean \pm SEM) before (averaged from -1 to 0 min) and after (averaged from 9 to 10 min) application of PBu_3 ($n = 27$ cells for Control and 26 cell for SIRT3 from nine different experiments). *Indicates $P < 0.05$ (t -test). Scale bar indicates $20\mu\text{m}$.

mitochondrial inner membrane potential induced by carbonyl cyanide *p*-(trifluoromethoxy) phenylhydrazone (FCCP) elicited a greater decrease in ATP (see Supplementary Fig. S4). While the levels of decrease were comparable to those induced by PBu_3 , the rate of decrease induced by these inhibitors was faster, suggesting that the inhibition of mitochondrial ATP synthesis by PBu_3 is moderate by comparison. Moreover, we observed PBu_3 -induced modulation of mitochondrial ATP concentration in cells of the non-cancerous tissue-derived cell line HEK293 (see Supplementary Fig. S5).




Figure 5. Pre-treatment with PBU₃ changed the response to pyruvate. (A) Time-course of the change in mitochondrial ATP concentration (mean \pm SEM) in control cells (blue line; $n = 61$ cells from five different experiments) and PBU₃-treated cells (red line; $n = 51$ cells from five different experiments). The PBU₃-treated cells were exposed to 5 mM of PBU₃ 10 min prior to the fluorescence measurements. Pyruvate (5 mM) was applied at 0 min. (B) Pseudo-colored images of control cells (upper panel) and PBU₃-treated cells (lower panel). Pseudo-colored images show an ATeam ratio (YFP/CFP) ranging from 0.9 (blue) to 1.4 (red) at the indicated time after the application of pyruvate (5mM). Scale bar indicates 20 μ m.

PBU₃ therefore promoted the acetyltransfer reaction from acetyl-CoA to mitochondrial proteins, which inhibited ATP production in mitochondria. Although acetyl-CoA is normally an essential substrate in mitochondrial energy production, mitochondrial ATP concentrations are decreased by PBU₃-induced protein acetylation involving acetyl-CoA. We next assessed whether the dominant role of acetyl-CoA in the PBU₃-treated cells was to act as a substrate for the TCA cycle or protein acetylation. To address this, changes in the mitochondrial ATP concentration in response to pyruvate were compared between control and PBU₃-treated cells, because acetyl-CoA is produced through pyruvate decarboxylation. In the control cells, pyruvate (5 mM) induced a transient increase in mitochondrial ATP concentration (Fig. 5A blue line and B upper panels). In contrast, it decreased ATP concentrations in the PBU₃-treated cells (Fig. 5A red line and B lower panels). These results indicate that acetyl-CoA contributes predominantly to protein acetylation in the presence of PBU₃, which results in the further decrease in ATP concentrations.

PBU₃-induced protein acetylation elicited alterations in mitochondrial morphology. Recent studies have reported that the acetylation and deacetylation of mitochondrial proteins regulates mitochondrial fusion and fission, resulting in alterations in mitochondrial morphology^{10,11}. These studies showed that mitochondria are fragmented in cells defective for SIRT3 or with a mutation in its downstream protein, and indicated that hyperacetylation elicits mitochondrial fragmentation, while deacetylation reverses this process.




Figure 6. PBU₃ induced reversible mitochondrial fragmentation. The mitochondrial shape was visualized using TagCFP-mito. (A) Elongated mitochondria were observed prior to the application of PBU₃. (B) Fragmented mitochondria were observed after incubation in PBU₃ (5 mM) containing medium for 10 min at 37 °C on a stage top incubator. (C) 10 min after the PBU₃ was washed out, the mitochondria returned to a linear shape. (a–f) Magnified areas of the images (a,b in A; c,d in B; and e,f in C). Scale bar indicates 20 μm. Data in this figure are representative of five experiments.




Figure 7. Schematic diagram of the results of this work.

To demonstrate this process directly, we monitored mitochondrial shapes with mitochondria targeted TagCFP, before and after the application of PBU₃. PBU₃ induced mitochondrial fragmentation within 10 min (Fig. 6A,B). Furthermore, the mitochondria returned to their normal shapes in 10 min after the PBU₃ was washed out (Fig. 6C). In SIRT3-overexpressing cells, the effect of PBU₃ appeared to be attenuated (see Supplementary Fig. S6). These results indicate that PBU₃-induced protein acetylation reversibly regulates mitochondrial morphology, and that acetylation-induced mitochondrial morphological change occurs quickly, within 10 min. Based on these results, we conclude that our method involving PBU₃ successfully modulates mitochondrial functions *via* mitochondrial protein acetylation, which enabled us to observe the time-course of the effects in mitochondria.

Discussion

In this study, we have shown that PBU₃ promotes mitochondrial protein acetylation and modulates mitochondrial functions. PBU₃ has been used as a catalyst in the acylation reaction²⁸. It also catalyses the reaction in living cells, as shown in our previous study using a newly developed fluorescent probe¹⁵. The chemicals that promote the specific reaction intracellularly are referred to as “artificial reaction promoters”. In our previous studies, these molecules were used to promote the reaction between specific biological molecules and fluorescent probes, which allowed us to measure biological molecules, such as acetyl-CoA and NAD(P)H, using the fluorescence imaging method^{15,29}. In this study, the artificial reaction promoter, PBU₃, was used to non-invasively promote the reaction between the biological molecules, acetyl-CoA and mitochondrial proteins (Figs 1–3), and to modulate mitochondrial functions in living cells (Figs 4–6) as summarized in Fig. 7. Our data show that PBU₃ promotes the reaction between acetyl-CoA and mitochondrial proteins, and modulates mitochondrial functions, at least in part, *via* the protein acetylation, although there might be other route. PBU₃ is therefore a useful tool for the control of cellular functions. To our knowledge, this is the first report to demonstrate the modulation of cellular function *via* the promotion of a specific chemical reaction in living cells.

While the protein acetylation process in mitochondria is not fully understood, the non-enzymatic chemical reaction between acetyl-CoA and lysine residues might be sufficient to explain mitochondrial protein

acetylation³⁰. If there is a sufficient amount of acetyl-CoA to maintain the protein acetylation state in mitochondria in contrast to the other compartments in the cell, it makes sense that PBu₃ induces protein acetylation specifically in mitochondria. Acetylation of mitochondrial proteins negatively regulates mitochondrial functions in many cases¹⁴. In this study, we demonstrated that PBu₃-induced acetylation down-regulates mitochondrial ATP production (Figs 4 and 5) and elicits mitochondrial fragmentation (Fig. 6) in HeLa cells. Although energy metabolism in cancer cell lines is different from that in non-cancerous cells, we observed this effect of PBu₃ on mitochondrial ATP concentration in both the cancerous HeLa cells and the non-cancerous HEK293 cells (see Supplementary Fig. S5). These results indicate that the effects of PBu₃ shown here are not unique to cancer cells. In addition to the processes observed in this study, mitochondrial protein acetylation is also related to oxidative damage^{11,31}, fatty acid oxidation², mitochondrial autophagy^{32,33}, and apoptosis¹⁷. These mechanisms are important for maintaining the normal functions of cells and tissues; hence, abnormal acetylation of mitochondrial proteins has been implicated in a number of diseases, such as metabolic syndromes³⁴, diabetes³⁵, Parkinson's disease³⁶, and Alzheimer's disease³⁷. Using PBu₃ at suitable concentrations, protein acetylation levels in mitochondria can be reversibly controlled without the knockout or inhibition of acetyltransferase. Reversible regulation of this significant physiological process might therefore be a powerful tool for investigating the pathogenesis of these diseases.

Recent studies have reported methods referred to as “bioorthogonal chemistry”, which allow artificial reactions to proceed in the cellular environments^{38,39}. These methods enable the occurrence of specific reactions between artificially-induced compounds, or between endogenous molecules and artificially-induced compounds, for tagging and probing intracellular molecules in living cells^{40,41}. In contrast, our method enhances a specific reaction between intrinsic biological molecules in living cells. Modulating biological reactions and functions without the knockout or inhibition of proteins is a novel approach to understanding intracellular events and physiological functions in living cells. We refer to this concept as “bioparallel chemistry”²⁹. With the use of artificial reaction promoters, cellular functions other than protein acetylation might be controlled. These methods can reveal novel aspects of chemical reactions under physiological conditions, and allow for the control of cellular functions.

Methods

Cell Culture. HeLa cells and HEK293 cells were cultured in DMEM supplemented with 10% (v/v) FBS and 1% (v/v) penicillin/ streptomycin in an incubator maintained at 37 °C and with a humidified atmosphere of 5% CO₂. For the fluorescence measurements, the cells were seeded onto glass-based dishes.

Fluorescence measurements. Changes in cytoplasmic and mitochondrial ATP concentrations were measured using an ATP sensor protein, ATeam, localized to the cytoplasm and mitochondria, respectively²³. Mitochondrial shapes in the HeLa cells were visualized using TagCFP-mito (Evrogen, Moscow, Russia). The plasmids coding for ATeam or TagCFP-mito were transfected into HeLa cells using Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA) one day before the fluorescence measurements were conducted. DNA coding human SIRT3 was cloned from HeLa cell cDNA and inserted to the pmCherry-N1 vector using the BglII and EcoRI restriction enzyme sites, then transfected into HeLa cells following ATeam-transfection. The bath solution was changed to Hanks' balanced salt solutions (HBSS) containing (in mM): NaCl, 137; KCl, 5.4; CaCl₂, 1.3; MgCl₂, 0.5; MgSO₄, 0.4; Na₂HPO₄, 0.3; KH₂PO₄, 0.4; NaHCO₃, 4.2; D-Glucose, 5.6; HEPES, 5 (pH adjusted to 7.4 with NaOH) before the fluorescence measurements were conducted.

Fluorescence imaging was performed using a confocal laser scanning microscope system (FluoView FV1000; Olympus, Tokyo, Japan) mounted on an inverted microscope (IX81; Olympus) with 40 × and 60 × oil-immersion objective lenses. The temperature of the microscope stage was maintained at 37 °C during the experiments using a stage top incubator (IN-OIN-F2, Tokai hit, Shizuoka, Japan). TagCFP-mito was excited at 440 nm with a laser diode, and a signal was observed at 460–560 nm. ATeam was excited at 440 nm, and the fluorescence signals were separated using a 510 nm dichroic mirror and observed at 460–500 nm for CFP and 515–615 nm for YFP. Fluorescence images were acquired and analysed with the FluoView software package (Olympus). Fluorescence intensities were calculated as mean intensity over a defined region of interest (ROI) containing the entire cell body of each cell.

Western Blotting. Control and PBu₃-treated cells were harvested and the mitochondria, cytoplasm, and nucleus isolated using the Mitochondria Isolation Kit (BioChain Institute, Gibbstown, NJ, USA). The samples were lysed in RIPA buffer containing 25 mM HEPES, 1.5% TritonX-100 (v/v), 1.0% sodium-deoxycholate (w/v), 0.1% SDS (w/v), 500 mM NaCl, 5 mM EDTA, 50 mM NaF, 100 μM Na₃VO₄, and 0.1 mg/mL leupeptin and protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan). The protein lysates were diluted to the same protein concentrations, separated using SDS-PAGE, transferred onto a PVDF membrane (Millipore, Billerica, MA, USA), and probed with an acetylated lysine-specific antibody (Sigma-Aldrich, St. Louis, MO, USA). The secondary antibody used was a horseradish peroxidase (HRP)-conjugated anti mouse IgG (GE Healthcare, Little Chalfont, UK). The ECL Western blotting detection system (Millipore) was used for detection with imaging by LAS-1000 (Fuji Film, Tokyo, Japan). After detecting acetylated lysine signals, the HRP conjugated to the secondary antibody was inactivated by incubating the membrane in 15% H₂O₂ for 30 min. Loading control proteins were then probed with a β-actin-specific antibody for the cytoplasmic protein sample, a Cox4-specific antibody for the mitochondrial protein sample, and a PARP1-specific antibody for the nuclear protein sample (GeneTex, Irvine, CA, USA). The secondary antibody was HRP-conjugated anti rabbit IgG (GE Healthcare) and the signals were detected as described above.

Quantification of Acetyl-CoA. Control and PBu₃-treated (5 mM for 10 min) cells were harvested in ice-cold PBS and sonicated. The protein concentration of each sample was estimated using Coomassie Brilliant

Blue (CBB) protein assay. The cell lysates were deproteinised using the Deproteinising Sample Preparation kit (BioVision, Milpitas, CA, USA). The acetyl-CoA concentration was then quantified using the PicoProbe Acetyl CoA Assay kit (BioVision). The probe was excited at 535 nm and the fluorescence measured at 589 nm using a microplate reader (Fluoroskan Ascent FL, Thermo Fisher Scientific, Waltham, MA, USA). The concentration was normalized using the protein concentration of each sample.

Identification of acetylated proteins. Mitochondrial protein samples were separated using SDS-PAGE, and the gel was stained using the Silver Stain MS kit (Wako, Osaka, Japan). The gel was cut at an appropriate position, and proteins contained in the gel fragment were digested using 20 ng/mL Trypsine. The digested proteins were eluted and resolved in elution buffer (50% acetonitrile and 5% trifluoroacetic acid). The sample was analysed using LC-MS/MS (Impact HD, Bruker Daltonics, Billerica, MA, USA).

Measurement of cell viability. Cell viability was measured using the MTT assay. After the cells had been exposed to PBu_3 -containing medium, this was replaced with a medium containing 0.5 mg/mL of MTT. The cells were incubated for 2 h at 37 °C. The medium was removed and 100 μL of DMSO was added to each well to dissolve the precipitate. Absorbance at 570 nm was measured using a microplate reader. Values from control cells were used to estimate the cell viability.

Statistical Analysis. Significant differences between two data-sets were determined using the Student's *t*-test, and the Dunnett's test was used for multiple comparisons. *P* values lower than 0.05 were considered significant.

References

- Newman, J. C., He, W. & Verdin, E. Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. *J Biol Chem.* **287**, 42436–42443 (2012).
- Hirsche, M. D. *et al.* SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. *Nature.* **464**, 121–125 (2010).
- Rardin, M. J. *et al.* Label-free quantitative proteomics of the lysine acetylome in mitochondria identifies substrates of SIRT3 in metabolic pathways. *Proc Natl Acad Sci USA* **110**, 6601–6606 (2013).
- Rauh, D. *et al.* An acetylome peptide microarray reveals specificities and deacetylation substrates for all human sirtuin isoforms. *Nat Commun.* **4**, 2327 (2013).
- Hebert, A. S. *et al.* Calorie restriction and SIRT3 trigger global reprogramming of the mitochondrial protein acetylome. *Mol Cell.* **49**, 186–199 (2013).
- Wu, Y. T., Lee, H. C., Liao, C. C. & Wei, Y. H. Regulation of mitochondrial F_1F_0 ATPase activity by Sirt3-catalyzed deacetylation and its deficiency in human cells harboring 4977bp deletion of mitochondrial DNA. *Biochim Biophys Acta.* **1832**, 216–227 (2013).
- Cimen, H. *et al.* Regulation of succinate dehydrogenase activity by SIRT3 in mammalian mitochondria. *Biochemistry.* **49**, 304–311 (2010).
- Bause, A. S., Matsui, M. S. & Haigis, M. C. The Protein Deacetylase SIRT3 Prevents Oxidative Stress-induced Keratinocyte Differentiation. *J Biol Chem.* **288**, 36484–36491 (2013).
- Rato, L. *et al.* Pre-diabetes alters testicular PGC1- α /SIRT3 axis modulating mitochondrial bioenergetics and oxidative stress. *Biochim Biophys Acta.* **1837**, 335–344 (2014).
- Samant, S. A. *et al.* SIRT3 Deacetylates and Activates OPA1 To Regulate Mitochondrial Dynamics during Stress. *Mol Cell Biol.* **34**, 807–819 (2014).
- Tseng, A. H., Shieh, S. S. & Wang, D. L. SIRT3 deacetylates FOXO3 to protect mitochondria against oxidative damage. *Free Radic Biol Med.* **63**, 222–234 (2013).
- Scott, I., Webster, B. R., Li, J. H. & Sack, M. N. Identification of a molecular component of the mitochondrial acetyltransferase programme: a novel role for GCN5L1. *Biochem J.* **443**, 655–661 (2012).
- Wagner, G. R. & Payne, R. M. Widespread and enzyme-independent Nepsilon-acetylation and Nepsilon-succinylation of proteins in the chemical conditions of the mitochondrial matrix. *J Biol Chem.* **288**, 29036–29045 (2013).
- Baeza, J., Smallegan, M. J. & Denu, J. M. Mechanisms and Dynamics of Protein Acetylation in Mitochondria. *Trends Biochem Sci* (2016).
- Komatsu, H. *et al.* Intracellular activation of acetyl-CoA by an artificial reaction promoter and its fluorescent detection. *Chem Commun (Camb).* **49**, 2876–2878 (2013).
- Hafner, A. V. *et al.* Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. *Aging (Albany NY).* **2**, 914–923 (2010).
- Li, S. *et al.* p53-induced growth arrest is regulated by the mitochondrial Sirt3 deacetylase. *PLoS One.* **5**, e10486 (2010).
- Yu, W., Dittenhafer-Reed, K. E. & Denu, J. M. SIRT3 protein deacetylates isocitrate dehydrogenase 2 (IDH2) and regulates mitochondrial redox status. *J Biol Chem.* **287**, 14078–14086 (2012).
- Cheng, A. *et al.* Mitochondrial SIRT3 Mediates Adaptive Responses of Neurons to Exercise and Metabolic and Excitatory Challenges. *Cell Metab.* **23**, 128–142 (2016).
- Jin, L. *et al.* Crystal structures of human SIRT3 displaying substrate-induced conformational changes. *J Biol Chem.* **284**, 24394–24405 (2009).
- Jaberi, E. *et al.* The novel mutation p.Asp251Asn in the beta-subunit of succinate-CoA ligase causes encephalomyopathy and elevated succinylcarnitine. *J Hum Genet.* **58**, 526–530 (2013).
- Fang, L. *et al.* Inactivation of MARCH5 prevents mitochondrial fragmentation and interferes with cell death in a neuronal cell model. *PLoS One.* **7**, e52637 (2012).
- Imamura, H. *et al.* Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. *Proc Natl Acad Sci USA* **106**, 15651–15656 (2009).
- Fritz, K. S., Galligan, J. J., Hirsche, M. D., Verdin, E. & Petersen, D. R. Mitochondrial acetylome analysis in a mouse model of alcohol-induced liver injury utilizing SIRT3 knockout mice. *J Proteome Res.* **11**, 1633–1643 (2012).
- Schwer, B., Bunkenborg, J., Verdin, R. O., Andersen, J. S. & Verdin, E. Reversible lysine acetylation controls the activity of the mitochondrial enzyme acetyl-CoA synthetase 2. *Proc Natl Acad Sci USA* **103**, 10224–10229 (2006).
- Ahn, B. H. *et al.* A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. *Proc Natl Acad Sci USA* **105**, 14447–14452 (2008).
- Ozden, O. *et al.* SIRT3 deacetylates and increases pyruvate dehydrogenase activity in cancer cells. *Free Radic Biol Med.* **76**, 163–172 (2014).
- Vedejs, E. & Diver, S. T. Tributylphosphine: A remarkable acylation catalyst. *J Am Chem Soc.* **115**, 3358–3359 (1993).

29. Komatsu, H., Shindo, Y., Oka, K., Hill, J. P. & Ariga, K. Ubiquinone-Rhodol (UQ-Rh) for Fluorescence Imaging of NAD(P)H through Intracellular Activation. *Angew Chem Int Ed Engl* (2014).
30. Baeza, J., Smallegan, M. J. & Denu, J. M. Site-specific reactivity of nonenzymatic lysine acetylation. *ACS Chem Biol.* **10**, 122–128 (2015).
31. Someya, S. *et al.* Sirt3 mediates reduction of oxidative damage and prevention of age-related hearing loss under caloric restriction. *Cell.* **143**, 802–812 (2010).
32. Guedes-Dias, P. & Oliveira, J. M. Lysine deacetylases and mitochondrial dynamics in neurodegeneration. *Biochim Biophys Acta.* **1832**, 1345–1359 (2013).
33. Webster, B. R. *et al.* Restricted mitochondrial protein acetylation initiates mitochondrial autophagy. *J Cell Sci.* **126**, 4843–4849 (2013).
34. Hirsche, M. D. *et al.* SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. *Mol Cell.* **44**, 177–190 (2011).
35. Vazquez, E. J. *et al.* Mitochondrial complex I defect and increased fatty acid oxidation enhance protein lysine acetylation in the diabetic heart. *Cardiovasc Res.* **107**, 453–465 (2015).
36. Hu, W., Guan, L. S., Dang, X. B., Ren, P. Y. & Zhang, Y. L. Small-molecule inhibitors at the PSD-95/nNOS interface attenuate MPP⁺-induced neuronal injury through Sirt3 mediated inhibition of mitochondrial dysfunction. *Neurochem Int.* **79**, 57–64 (2014).
37. Yang, W. *et al.* Mitochondrial Sirt3 Expression is Decreased in APP/PS1 Double Transgenic Mouse Model of Alzheimer's Disease. *Neurochem Res.* **40**, 1576–1582 (2015).
38. Grammel, M. & Hang, H. C. Chemical reporters for biological discovery. *Nat Chem Biol.* **9**, 475–484 (2013).
39. Patterson, D. M., Nazarova, L. A. & Prescher, J. A. Finding the right (bioorthogonal) chemistry. *ACS Chem Biol.* **9**, 592–605 (2014).
40. Beatty, K. E., Xie, F., Wang, Q. & Tirrell, D. A. Selective dye-labeling of newly synthesized proteins in bacterial cells. *J Am Chem Soc.* **127**, 14150–14151 (2005).
41. Yusop, R. M., Unciti-Broceta, A., Johansson, E. M., Sanchez-Martin, R. M. & Bradley, M. Palladium-mediated intracellular chemistry. *Nat Chem.* **3**, 239–243 (2011).

Acknowledgements

We thank Dr. H. Imamura and Dr. H. Noji for providing the ATeam plasmid. This research was supported by the Grant-in-Aid for Scientific Research, KAKENHI (24240045 and 25750395).

Author Contributions

Y.S. designed the study, performed the experiments, analysed the data, and wrote the paper. H.K. designed the study and edited the paper. K.H. and K.A. designed the study. K.O. designed the study and edited the paper. All authors reviewed the manuscript.

Additional Information

Supplementary information accompanies this paper at <http://www.nature.com/srep>

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Shindo, Y. *et al.* An Artificial Reaction Promoter Modulates Mitochondrial Functions via Chemically Promoting Protein Acetylation. *Sci. Rep.* **6**, 29224; doi: 10.1038/srep29224 (2016).



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>